Agree about trial design. The attention composite results seem completely inconclusive in my opinion, not necessarily as negative as the market is reacting however. The 2 groups of patients start nowhere near each other and that placebo effect seems unprecedented and not very well explained by ACW team, if it remained in expected range we would have a winner. Follow up shows placebo group start decreasing while xanemem continue to improve so that seems good at least. Other indicators seem positive. Overall disappointed by the trial results but ultimately not discouraged.
- Forums
- ASX - By Stock
- ACW
- Ann: ACW XanaCIDD phase 2a trial topline results
Ann: ACW XanaCIDD phase 2a trial topline results, page-55
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACW (ASX) to my watchlist
|
|||||
Last
3.1¢ |
Change
-0.045(59.2%) |
Mkt cap ! $84.06M |
Open | High | Low | Value | Volume |
3.0¢ | 3.7¢ | 2.5¢ | $3.093M | 99.90M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 2638151 | 3.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.2¢ | 1623309 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 400000 | 0.033 |
2 | 68754 | 0.032 |
9 | 765287 | 0.031 |
8 | 1697272 | 0.030 |
8 | 1064705 | 0.029 |
Price($) | Vol. | No. |
---|---|---|
0.031 | 420093 | 4 |
0.032 | 2342401 | 9 |
0.033 | 2427203 | 11 |
0.034 | 1487252 | 6 |
0.035 | 3454058 | 10 |
Last trade - 16.10pm 12/08/2024 (20 minute delay) ? |
Featured News
ACW (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online